Contact
searchSearch
HMP Global
Login

Thyroid Cancer Specialty Channel

News
High-Sensitivity Calcitonin Testing Establishes New Cutoffs for Nodal Metastasis in Medullary Thyroid Cancer
12/04/2025
Stephanie Holland
Results from a large multicenter cohort study demonstrate that contemporary high-sensitivity calcitonin assays significantly revise established serum calcitonin thresholds for predicting lymph node metastases in medullary thyroid cancer.
Results from a large multicenter cohort study demonstrate that contemporary high-sensitivity calcitonin assays significantly revise established serum calcitonin thresholds for predicting lymph node metastases in medullary thyroid cancer.
Results from a large multicenter...
12/04/2025
Oncology
Quiz
Dabrafenib Plus Trametinib in BRAF V600E-Mutated Thyroid Cancer
12/01/2025
Which of the following statements best summarizes efficacy findings from a phase 3 trial evaluating dabrafenib plus trametinib in patients with BRAF V600E–mutated, radioiodine-refractory thyroid cancer who had previously received...
Which of the following statements best summarizes efficacy findings from a phase 3 trial evaluating dabrafenib plus trametinib in patients with BRAF V600E–mutated, radioiodine-refractory thyroid cancer who had previously received...
Which of the following...
12/01/2025
Oncology
News
Dabrafenib Plus Trametinib Shows Significant Clinical Benefit in BRAF V600E-Mutated Thyroid Cancer
11/07/2025
Stephanie Holland
Results from a phase 3 trial demonstrated that dabrafenib plus trametinib significantly improved survival and response rates among patients with BRAF V600E-mutated, radioiodine-refractory thyroid cancer.
Results from a phase 3 trial demonstrated that dabrafenib plus trametinib significantly improved survival and response rates among patients with BRAF V600E-mutated, radioiodine-refractory thyroid cancer.
Results from a phase 3 trial...
11/07/2025
Oncology
News
Implications of PD-L1 Positivity for Patients With Papillary Thyroid Cancer
10/09/2025
Allison Casey
According to a retrospective, real-world analysis, PD-L1 positivity was found to be associated with multiple adverse features and an increased risk of recurrence among a cohort of Greek patients with papillary thyroid cancer.
According to a retrospective, real-world analysis, PD-L1 positivity was found to be associated with multiple adverse features and an increased risk of recurrence among a cohort of Greek patients with papillary thyroid cancer.
According to a retrospective,...
10/09/2025
Oncology
Quiz
Trimodal Therapy for Patients With Anaplastic Thyroid Cancer
08/19/2025
A retrospective analysis of 3460 patients with anaplastic thyroid cancer compared outcomes by the number of treatment modalities used. Which of the following statements best illustrates study findings?
A retrospective analysis of 3460 patients with anaplastic thyroid cancer compared outcomes by the number of treatment modalities used. Which of the following statements best illustrates study findings?
A retrospective analysis of 3460...
08/19/2025
Oncology
News
The Benefit of Trimodal Therapy for Anaplastic Thyroid Cancer
08/07/2025
Allison Casey
According to a retrospective study, patients with anaplastic thyroid cancer who received trimodal therapy had a statistically significant improvement to overall survival compared to those patients who received less intensive therapy.
According to a retrospective study, patients with anaplastic thyroid cancer who received trimodal therapy had a statistically significant improvement to overall survival compared to those patients who received less intensive therapy.
According to a retrospective...
08/07/2025
Oncology
Quiz
Neoadjuvant Pembrolizumab Plus Dabrafenib and Trametinib for Patients With BRAF V600E-Mutated Anaplastic Thyroid Cancer
07/29/2025
True or False: According to a phase 2 study, neoadjuvant pembrolizumab with dabrafenib and trametinib enabled surgical resection among patients with BRAF V600E-mutated anaplastic thyroid cancer, leading to improved progression-free survival...
True or False: According to a phase 2 study, neoadjuvant pembrolizumab with dabrafenib and trametinib enabled surgical resection among patients with BRAF V600E-mutated anaplastic thyroid cancer, leading to improved progression-free survival...
True or False: According to a...
07/29/2025
Oncology
News
Causes of Deaths Among Patients With Differentiated Thyroid Cancer
07/17/2025
Allison Casey
According to a retrospective study, a substantial proportion of deaths among patients with metastatic DTC were due to non–cancer-related causes.
According to a retrospective study, a substantial proportion of deaths among patients with metastatic DTC were due to non–cancer-related causes.
According to a retrospective...
07/17/2025
Oncology
News
Impact of Postoperative Issues on Sleep Quality Following Thyroidectomy
06/25/2025
Allison Casey
A descriptive, prospective study found a significant decrease in sleep quality after patients with thyroid cancer had undergone thyroidectomy.
A descriptive, prospective study found a significant decrease in sleep quality after patients with thyroid cancer had undergone thyroidectomy.
A descriptive, prospective study...
06/25/2025
Oncology
Conference Coverage
Neoadjuvant Pembrolizumab Plus Dabrafenib and Trametinib Improved Outcomes for Patients With BRAF-Mutated Anaplastic Thyroid Cancer
06/18/2025
Allison Casey
According to results from a phase 2 trial, neoadjuvant pembrolizumab with dabrafenib and trametinib improved R1/R0 resection rates, progression-free survival, and overall survival among patients with BRAF V600E-mutated anaplastic thyroid...
According to results from a phase 2 trial, neoadjuvant pembrolizumab with dabrafenib and trametinib improved R1/R0 resection rates, progression-free survival, and overall survival among patients with BRAF V600E-mutated anaplastic thyroid...
According to results from a...
06/18/2025
Oncology
News
Use of Patient-Derived Organoids-Based Testing to Guide Neoadjuvant Treatment for Patients With Locally Advanced Thyroid Cancer
05/06/2025
Allison Casey
According to a single arm, phase 2 study, using patient-derived organoids-based testing has potential in guiding neoadjuvant therapy among patients with locally advanced thyroid cancer.
According to a single arm, phase 2 study, using patient-derived organoids-based testing has potential in guiding neoadjuvant therapy among patients with locally advanced thyroid cancer.
According to a single arm, phase...
05/06/2025
Oncology

News

News
High-Sensitivity Calcitonin Testing Establishes New Cutoffs for Nodal Metastasis in Medullary Thyroid Cancer
12/04/2025
Stephanie Holland
Results from a large multicenter cohort study demonstrate that contemporary high-sensitivity calcitonin assays significantly revise established serum calcitonin thresholds for predicting lymph node metastases in medullary thyroid cancer.
Results from a large multicenter cohort study demonstrate that contemporary high-sensitivity calcitonin assays significantly revise established serum calcitonin thresholds for predicting lymph node metastases in medullary thyroid cancer.
Results from a large multicenter...
12/04/2025
Oncology
News
Dabrafenib Plus Trametinib Shows Significant Clinical Benefit in BRAF V600E-Mutated Thyroid Cancer
11/07/2025
Stephanie Holland
Results from a phase 3 trial demonstrated that dabrafenib plus trametinib significantly improved survival and response rates among patients with BRAF V600E-mutated, radioiodine-refractory thyroid cancer.
Results from a phase 3 trial demonstrated that dabrafenib plus trametinib significantly improved survival and response rates among patients with BRAF V600E-mutated, radioiodine-refractory thyroid cancer.
Results from a phase 3 trial...
11/07/2025
Oncology
News
Implications of PD-L1 Positivity for Patients With Papillary Thyroid Cancer
10/09/2025
Allison Casey
According to a retrospective, real-world analysis, PD-L1 positivity was found to be associated with multiple adverse features and an increased risk of recurrence among a cohort of Greek patients with papillary thyroid cancer.
According to a retrospective, real-world analysis, PD-L1 positivity was found to be associated with multiple adverse features and an increased risk of recurrence among a cohort of Greek patients with papillary thyroid cancer.
According to a retrospective,...
10/09/2025
Oncology
News
The Benefit of Trimodal Therapy for Anaplastic Thyroid Cancer
08/07/2025
Allison Casey
According to a retrospective study, patients with anaplastic thyroid cancer who received trimodal therapy had a statistically significant improvement to overall survival compared to those patients who received less intensive therapy.
According to a retrospective study, patients with anaplastic thyroid cancer who received trimodal therapy had a statistically significant improvement to overall survival compared to those patients who received less intensive therapy.
According to a retrospective...
08/07/2025
Oncology
News
Causes of Deaths Among Patients With Differentiated Thyroid Cancer
07/17/2025
Allison Casey
According to a retrospective study, a substantial proportion of deaths among patients with metastatic DTC were due to non–cancer-related causes.
According to a retrospective study, a substantial proportion of deaths among patients with metastatic DTC were due to non–cancer-related causes.
According to a retrospective...
07/17/2025
Oncology
News
Impact of Postoperative Issues on Sleep Quality Following Thyroidectomy
06/25/2025
Allison Casey
A descriptive, prospective study found a significant decrease in sleep quality after patients with thyroid cancer had undergone thyroidectomy.
A descriptive, prospective study found a significant decrease in sleep quality after patients with thyroid cancer had undergone thyroidectomy.
A descriptive, prospective study...
06/25/2025
Oncology
Conference Coverage
Neoadjuvant Pembrolizumab Plus Dabrafenib and Trametinib Improved Outcomes for Patients With BRAF-Mutated Anaplastic Thyroid Cancer
06/18/2025
Allison Casey
According to results from a phase 2 trial, neoadjuvant pembrolizumab with dabrafenib and trametinib improved R1/R0 resection rates, progression-free survival, and overall survival among patients with BRAF V600E-mutated anaplastic thyroid...
According to results from a phase 2 trial, neoadjuvant pembrolizumab with dabrafenib and trametinib improved R1/R0 resection rates, progression-free survival, and overall survival among patients with BRAF V600E-mutated anaplastic thyroid...
According to results from a...
06/18/2025
Oncology
News
Use of Patient-Derived Organoids-Based Testing to Guide Neoadjuvant Treatment for Patients With Locally Advanced Thyroid Cancer
05/06/2025
Allison Casey
According to a single arm, phase 2 study, using patient-derived organoids-based testing has potential in guiding neoadjuvant therapy among patients with locally advanced thyroid cancer.
According to a single arm, phase 2 study, using patient-derived organoids-based testing has potential in guiding neoadjuvant therapy among patients with locally advanced thyroid cancer.
According to a single arm, phase...
05/06/2025
Oncology
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
Allison Casey
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Oncology
News
Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer
04/01/2025
Allison Casey
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of...
04/01/2025
Oncology

Interactive Features

Quiz
Dabrafenib Plus Trametinib in BRAF V600E-Mutated Thyroid Cancer
12/01/2025
Which of the following statements best summarizes efficacy findings from a phase 3 trial evaluating dabrafenib plus trametinib in patients with BRAF V600E–mutated, radioiodine-refractory thyroid cancer who had previously received...
Which of the following statements best summarizes efficacy findings from a phase 3 trial evaluating dabrafenib plus trametinib in patients with BRAF V600E–mutated, radioiodine-refractory thyroid cancer who had previously received...
Which of the following...
12/01/2025
Oncology
Quiz
Trimodal Therapy for Patients With Anaplastic Thyroid Cancer
08/19/2025
A retrospective analysis of 3460 patients with anaplastic thyroid cancer compared outcomes by the number of treatment modalities used. Which of the following statements best illustrates study findings?
A retrospective analysis of 3460 patients with anaplastic thyroid cancer compared outcomes by the number of treatment modalities used. Which of the following statements best illustrates study findings?
A retrospective analysis of 3460...
08/19/2025
Oncology
Quiz
Neoadjuvant Pembrolizumab Plus Dabrafenib and Trametinib for Patients With BRAF V600E-Mutated Anaplastic Thyroid Cancer
07/29/2025
True or False: According to a phase 2 study, neoadjuvant pembrolizumab with dabrafenib and trametinib enabled surgical resection among patients with BRAF V600E-mutated anaplastic thyroid cancer, leading to improved progression-free survival...
True or False: According to a phase 2 study, neoadjuvant pembrolizumab with dabrafenib and trametinib enabled surgical resection among patients with BRAF V600E-mutated anaplastic thyroid cancer, leading to improved progression-free survival...
True or False: According to a...
07/29/2025
Oncology
Test Your Knowledge
Quiz: Which Treatment Was Recently Granted FDA Approval for DTC?
12/06/2021
Which treatment was recently approved by the FDA for locally advanced or metastatic differentiated thyroid cancer?
Which treatment was recently approved by the FDA for locally advanced or metastatic differentiated thyroid cancer?
Which treatment was recently...
12/06/2021
Oncology
Test Your Knowledge
Quiz: Lenvatinib Monotherapy for Patients with Anaplastic Thyroid Cancer
09/01/2021
True or false: Results from a phase 2 trial suggest lenvatinib monotherapy may be an effective treatment for anaplastic thyroid cancer.
True or false: Results from a phase 2 trial suggest lenvatinib monotherapy may be an effective treatment for anaplastic thyroid cancer.
True or false: Results from a...
09/01/2021
Oncology
Quiz
Quiz: Efficacy of Vandetanib, Cabozantinib for Advanced MTCctive in Treating Advanced MTC?
06/21/2021
True or False: Results from a real-world study showed that vandetanib and cabozantinib were ineffective for the treatment of patients with advanced MTC.
True or False: Results from a real-world study showed that vandetanib and cabozantinib were ineffective for the treatment of patients with advanced MTC.
True or False: Results from a...
06/21/2021
Oncology
Test Your Knowledge
Quiz: Does Artificial LAN Increase the Risk of Thyroid Cancer?
04/05/2021
True or false: Artificial LAN may increase the risk of thyroid cancer?
True or false: Artificial LAN may increase the risk of thyroid cancer?
True or false: Artificial LAN...
04/05/2021
Oncology
Test Your Knowledge
Quiz: Has Selpercatinib Been Proven Effective in Thyroid Cancer?
02/01/2021
True or false: A phase 1/2 trial found Selpercatinib to be ineffective in patients with RET-mutant medullary thyroid cancer.
True or false: A phase 1/2 trial found Selpercatinib to be ineffective in patients with RET-mutant medullary thyroid cancer.
True or false: A phase 1/2 trial...
02/01/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment Was Recently Granted Accelerated Approval in RET-Altered Thyroid Cancers?
01/11/2021
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
Which of the following...
01/11/2021
Oncology
Test Your Knowledge
Quiz: The FDA Approved Pralsetinib For Which Type of Thyroid Cancer?
01/08/2021
The FDA recently approved pralsetinib for RET-altered _______ thyroid cancer.
The FDA recently approved pralsetinib for RET-altered _______ thyroid cancer.
The FDA recently approved...
01/08/2021
Oncology

Recent News

News
High-Sensitivity Calcitonin Testing Establishes New Cutoffs for Nodal Metastasis in Medullary Thyroid Cancer
12/04/2025
Stephanie Holland
Results from a large multicenter cohort study demonstrate that contemporary high-sensitivity calcitonin assays significantly revise established serum calcitonin thresholds for predicting lymph node metastases in medullary thyroid cancer.
Results from a large multicenter cohort study demonstrate that contemporary high-sensitivity calcitonin assays significantly revise established serum calcitonin thresholds for predicting lymph node metastases in medullary thyroid cancer.
Results from a large multicenter...
12/04/2025
Oncology
News
Dabrafenib Plus Trametinib Shows Significant Clinical Benefit in BRAF V600E-Mutated Thyroid Cancer
11/07/2025
Stephanie Holland
Results from a phase 3 trial demonstrated that dabrafenib plus trametinib significantly improved survival and response rates among patients with BRAF V600E-mutated, radioiodine-refractory thyroid cancer.
Results from a phase 3 trial demonstrated that dabrafenib plus trametinib significantly improved survival and response rates among patients with BRAF V600E-mutated, radioiodine-refractory thyroid cancer.
Results from a phase 3 trial...
11/07/2025
Oncology
News
Implications of PD-L1 Positivity for Patients With Papillary Thyroid Cancer
10/09/2025
Allison Casey
According to a retrospective, real-world analysis, PD-L1 positivity was found to be associated with multiple adverse features and an increased risk of recurrence among a cohort of Greek patients with papillary thyroid cancer.
According to a retrospective, real-world analysis, PD-L1 positivity was found to be associated with multiple adverse features and an increased risk of recurrence among a cohort of Greek patients with papillary thyroid cancer.
According to a retrospective,...
10/09/2025
Oncology
News
The Benefit of Trimodal Therapy for Anaplastic Thyroid Cancer
08/07/2025
Allison Casey
According to a retrospective study, patients with anaplastic thyroid cancer who received trimodal therapy had a statistically significant improvement to overall survival compared to those patients who received less intensive therapy.
According to a retrospective study, patients with anaplastic thyroid cancer who received trimodal therapy had a statistically significant improvement to overall survival compared to those patients who received less intensive therapy.
According to a retrospective...
08/07/2025
Oncology
News
Causes of Deaths Among Patients With Differentiated Thyroid Cancer
07/17/2025
Allison Casey
According to a retrospective study, a substantial proportion of deaths among patients with metastatic DTC were due to non–cancer-related causes.
According to a retrospective study, a substantial proportion of deaths among patients with metastatic DTC were due to non–cancer-related causes.
According to a retrospective...
07/17/2025
Oncology
News
Impact of Postoperative Issues on Sleep Quality Following Thyroidectomy
06/25/2025
Allison Casey
A descriptive, prospective study found a significant decrease in sleep quality after patients with thyroid cancer had undergone thyroidectomy.
A descriptive, prospective study found a significant decrease in sleep quality after patients with thyroid cancer had undergone thyroidectomy.
A descriptive, prospective study...
06/25/2025
Oncology
Conference Coverage
Neoadjuvant Pembrolizumab Plus Dabrafenib and Trametinib Improved Outcomes for Patients With BRAF-Mutated Anaplastic Thyroid Cancer
06/18/2025
Allison Casey
According to results from a phase 2 trial, neoadjuvant pembrolizumab with dabrafenib and trametinib improved R1/R0 resection rates, progression-free survival, and overall survival among patients with BRAF V600E-mutated anaplastic thyroid...
According to results from a phase 2 trial, neoadjuvant pembrolizumab with dabrafenib and trametinib improved R1/R0 resection rates, progression-free survival, and overall survival among patients with BRAF V600E-mutated anaplastic thyroid...
According to results from a...
06/18/2025
Oncology
News
Use of Patient-Derived Organoids-Based Testing to Guide Neoadjuvant Treatment for Patients With Locally Advanced Thyroid Cancer
05/06/2025
Allison Casey
According to a single arm, phase 2 study, using patient-derived organoids-based testing has potential in guiding neoadjuvant therapy among patients with locally advanced thyroid cancer.
According to a single arm, phase 2 study, using patient-derived organoids-based testing has potential in guiding neoadjuvant therapy among patients with locally advanced thyroid cancer.
According to a single arm, phase...
05/06/2025
Oncology
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
Allison Casey
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Oncology
News
Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer
04/01/2025
Allison Casey
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of...
04/01/2025
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use